Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 11/20 | 1.00 |
| ▸ | DRD2 | P14416 | 11/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 2/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | CASP1 | P29466 | 1/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.97 |
| ▸ | DRD1 | P21728 | 2/20 | 0.77 |
| ▸ | DRD4 | P21917 | 2/20 | 0.77 |
| ▸ | DRD5 | P21918 | 2/20 | 0.77 |
| ▸ | PRCP | P42785 | 1/20 | 0.67 |
| ▸ | EBP | Q15125 | 1/20 | 0.67 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7355118 | 1.00 | DRD3 (1.00) | DRD3DRD2NFKB1CYP2D6TSHR | |
| SCHEMBL7346180 | 1.00 | DRD3 (1.00) | DRD3DRD2NFKB1CYP2D6TSHR | |
| SCHEMBL7351587 | 0.93 | DRD3 (0.86) | DRD3DRD2NFKB1CYP2D6TSHR | |
| SCHEMBL7351002 | 0.92 | DRD3 (0.85) | DRD3DRD2NFKB1CYP2D6TSHR | |
| SCHEMBL19723276 | 0.90 | DRD3 (0.81) | DRD3DRD2NFKB1CYP2D6TSHR | |
| SCHEMBL7349038 | 0.90 | DRD3 (1.00) | DRD3DRD2NFKB1CYP2D6TSHR | |
| SCHEMBL7347167 | 0.87 | DRD3 (1.00) | DRD3DRD2NFKB1CYP2D6TSHR | |
| SCHEMBL4827536 | 0.85 | DRD2 (0.74) | DRD3DRD2NFKB1CYP2D6TSHR | |
| SCHEMBL7349233 | 0.84 | DRD3 (1.00) | DRD3DRD2NFKB1CYP2D6TSHR | |
| SCHEMBL7348713 | 0.84 | DRD3 (1.00) | DRD3DRD2NFKB1CYP2D6TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4694932-A2 | COMPOUNDS CONTAINING ONE OR MORE DIBORONATES AND RELATED INSULIN ANALOGS | Protomer Technologies Inc. (US) | 2026-02-18 | — | — | EP | claimed |
| WO-2024215876-A2 | COMPOUNDS CONTAINING ONE OR MORE DIBORONATES AND RELATED INSULIN ANALOGS | PROTOMER TECHNOLOGIES, INC. (US) | 2024-10-17 | — | — | WO | claimed |
| US-20130197032-A1 | PHENYLPIPERIDINE COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | A. CARLSSON RESEARCH AB (SE) | 2013-08-01 | — | — | US | claimed |
| EP-2618826-A1 | PHENYLPIPERIDINE COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | A.Carlsson Research AB (SE) | 2013-07-31 | — | — | EP | claimed |
| WO-2012039660-A1 | PHENYLPIPERIDINE COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | A. CARLSSON RESEARCH AB (SE) | 2012-03-29 | — | — | WO | claimed |
| EP-4747386-A1 | DOUBLE-STRANDED OLIGONUCLEOTIDE AGENTS AND USES THEREOF | Bisirna Therapeutics Pte. Ltd. (SG) | 2026-05-27 | — | — | EP | disclosed |
| EP-4694932-A2 | COMPOUNDS CONTAINING ONE OR MORE DIBORONATES AND RELATED INSULIN ANALOGS | Protomer Technologies Inc. (US) | 2026-02-18 | — | — | EP | disclosed |
| EP-3665274-B1 | VARIANTS OF FAMILY A DNA POLYMERASE AND USES THEREOF | DNA SCRIPT (FR) | 2025-10-15 | — | — | EP | disclosed |
| EP-4610356-A1 | RNA INHIBITOR FOR INHIBITING LPA GENE EXPRESSION AND USE THEREOF | Kylonova (Xiamen) Biopharma Co., Ltd. (CN) | 2025-09-03 | — | — | EP | disclosed |
| US-20250223575-A1 | VARIANTS OF TERMINAL DEOXYNUCLEOTIDYL TRANSFERASE AND USES THEREOF | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2025-07-10 | — | — | US | disclosed |
| EP-4567112-A1 | RNA INHIBITOR FOR INHIBITING APOC3 GENE EXPRESSION AND USE THEREOF | Kylonova (Xiamen) Biopharma Co., Ltd. (CN) | 2025-06-11 | — | — | EP | disclosed |
| US-12286652-B2 | Variants of terminal deoxynucleotidyl transferase and uses thereof | DNA SCRIPT (FR) | 2025-04-29 | — | — | US | disclosed |
| US-20130197032-A1 | PHENYLPIPERIDINE COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | A. CARLSSON RESEARCH AB (SE) | 2013-08-01 | — | — | US | disclosed |
| EP-2618826-A1 | PHENYLPIPERIDINE COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | A.Carlsson Research AB (SE) | 2013-07-31 | — | — | EP | disclosed |
| WO-2012039660-A1 | PHENYLPIPERIDINE COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | A. CARLSSON RESEARCH AB (SE) | 2012-03-29 | — | — | WO | disclosed |
| EP-0641320-B1 | SUBSTITUTED (S)-3-PHENYLPIPERIDINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS DOPAMINE AUTORECEPTOR ANTAGONISTS | UPJOHN CO (US) | 2001-05-30 | — | — | EP | disclosed |
| US-5594024-A | ANTIDEPRESSANTS; TREATMENT OF NARCOLEPSY, SCHIZOPHRENIA, DRUG ABUSE | THE UPJOHN COMPANY (US) | 1997-01-14 | — | — | US | disclosed |
| US-5462947-A | Nervous system disorders | THE UPJOHN COMPANY (US) | 1995-10-31 | — | — | US | disclosed |
| EP-0641320-A1 | NEW CENTRALLY ACTING SUBSTITUTED PHENYLAZACYCLOALKANES | PHARMACIA & UPJOHN COMPANY (US) | 1995-03-08 | — | — | EP | disclosed |
| WO-1992018475-A2 | SUBSTITUTED PHENYLAZACYCLOALKANES AS CNS AGENTS | THE UPJOHN COMPANY (US) | 1992-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130197032-A1 | PHENYLPIPERIDINE COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | HTR5A, HTR2A, HTR1A | DRD3 186/4885DRD2 36/4885NFKB1 1731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.